Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28636456 | 0.84 | MAPT (0.48) | MAPTLMNASMN1; SMN2CYP4Z1KDM4E | |
| SCHEMBL17315637 | 0.82 | RXRA (0.42) | LMNAKDM4EALDH1A1TSHRHSD17B10 | |
| SCHEMBL16278156 | 0.82 | SMN1; SMN2 (0.36) | MAPTLMNASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL1997052 | 0.82 | CA1 (0.49) | MAPTLMNASMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL18705952 | 0.79 | LPL (0.32) | — | |
| SCHEMBL1239798 | 0.79 | LPL (0.52) | MAPTLMNASMN1; SMN2CYP4Z1KDM4E | |
| SCHEMBL9986342 | 0.77 | PPARG (0.37) | TSHR | |
| SCHEMBL68851 | 0.76 | CYP4Z1 (0.62) | MAPTLMNASMN1; SMN2CYP4Z1KDM4E | |
| SCHEMBL1129027 | 0.76 | LPL (0.32) | — | |
| SCHEMBL1490590 | 0.76 | F11 (0.47) | SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643291-A2 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS | Leo Pharma A/S (DK) | 2013-10-02 | — | — | EP | disclosed |
| US-20130244995-A1 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2013-09-19 | — | — | US | disclosed |
| WO-2012069420-A2 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130244995-A1 | CALCIUM-SENSING RECEPTOR-ACTIVE COMPOUNDS | CASR, CALCR, PTH1R | MAPT 3151/4885LMNA 2262/4885SMN1; SMN2 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.